Teva-Cephalon deal's 'sole explanation' was avoiding competition, EU judges rule
Teva Pharmaceuticals has seen top EU judges reject its appeal over a €60.5 million antitrust fine for delaying the launch of a generic drug to challenge Cephalon's blockbuster Modafinil in exchange...To view the full article, register now.
Already a subscriber? Click here to view full article